Vanderbilt Vaccine Research Program

January 17, 2024

Bird flu vaccine more effective with potent adjuvant

The avian (bird) influenza vaccine creates a more robust immune response when paired with a potent ingredient known as an adjuvant, according to Vanderbilt research published in The Journal of Infectious Diseases.

By Craig Boerner
November 4, 2022

Study finds Moderna’s COVID-19 vaccine safe and effective for young children

A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.

By Bill Snyder
September 7, 2022

VUMC study will evaluate alternative strategies for administering mpox vaccine

Rarely fatal, the mpox virus — spread by close, often skin-to-skin contact — causes a painful, blistering rash, fever, chills and other symptoms.

By Bill Snyder
July 28, 2022

Study to evaluate nasal flu vaccine for children

Pediatricians with the Vanderbilt Vaccine Research Program are looking for healthy infants and children (6 months – 8 years of age) to take part in a nasal influenza vaccine study.

By Craig Boerner
May 12, 2022

VUMC-led study finds Moderna COVID vaccine safe and effective for children

By Bill Snyder
Amya Elliott, 9, talks with Bonnie Pilon, RN, prior to receiving her COVID-19 vaccination at Monroe Carell Jr. Children’s Hospital at Vanderbilt. The hospital began mass vaccination for children ages 5-11 on Monday, Nov. 8.
February 24, 2022

MIS-C diagnosis rare in vaccinated children with no previous COVID-19 diagnosis

A Vanderbilt study found that children who received the COVID-19 vaccine who had not previously been diagnosed with COVID infection are unlikely to be diagnosed with multisystem inflammatory syndrome in children (MIS-C).

By Kylie Avery
February 3, 2022

Study finds shorter treatment better for young children with outpatient pneumonia

A Vanderbilt study found that five days of antibiotics is superior to 10 days for children with community-acquired pneumonia who are not hospitalized.
By Craig Boerner
December 8, 2021

Weigh risks, plan ahead prior to gathering for the holidays

Vanderbilt University Medical Center infectious disease experts advise this is the season to think very wisely about planned get-togethers.
By Jill Clendening
May 12, 2021

Heparin, platelets discouraged as treatment for blood clots after COVID vaccine

Heparin and platelets are discouraged as treatment for patients who develop blood clots in the brain and low platelet counts 6-15 days after receiving Johnson & Johnson’s Janssen COVID-19 vaccine, following a clinical investigation review of 12 U.S. cases conducted by the CDC and institutions including Vanderbilt University Medical Center.
By Craig Boerner
April 2, 2021

Investigational vaccine to be tested against COVID-19 variant

Vanderbilt University Medical Center is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.
By Bill Snyder
December 16, 2020

Coronavirus ‘crusaders’ spur VUMC research achievements

The development of the vaccines, monoclonal antibodies and antiviral drugs that ultimately will defeat COVID-19 wouldn’t have been possible had it not been for the unflagging and selfless efforts of a global army of research nurses, laboratory personnel, recruiters and other staff.
By Bill Snyder
November 2, 2020

VUMC begins study of second COVID-19 vaccine

Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.
By Bill Snyder
June 4, 2020

Remdesivir helps reduce COVID-19 recovery time: study

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.
By Bill Snyder
1 2 3